Boyds is delighted to announce the promotion of Eric Hardter to Director of Regulatory Affairs.
Eric joined Boyds in 2023 as part of our ongoing expansion into the US.
Since that time, Eric has leveraged his previous experiences in the cell and gene therapy and rare disease spaces, with a focus on translational stage research as well as formal interaction with the FDA on behalf of our clients. He has also developed expertise and experience in oncology therapeutic development programs, late-phase clinical research, and deliverables to the European Medicines Agency, as well as supporting Boyds with US regulatory affairs business development.
His promotion is aligned with our growth plans to further expand our presence in the US, which will see Eric supervising new team members, as well as building our US processes, procedures and best practices.
Eric says: “As an American, moving from a US-based, mid-size contract research organization to a small, UK-based consultancy represented a major paradigm shift for me. While it took some time to acclimatize to such a massive cultural change, and though I still occasionally feel like I need a glossary for certain English jargon, I’m extremely happy to be here as part of the team.
“The culture at Boyds is one of professionalism and collaboration, devoid of pretense, and boasts a wide and diverse array of subject matter expertise. The work is varied and scientifically engaging, with opportunities to support a diversity of projects that will ultimately benefit public health. Most importantly, everyone is respectful and trusts in one another, and I truly appreciate that my colleagues don’t hesitate to come to me with any FDA-related questions. Boyds was also personally supportive of my wife and I moving our home from Maryland to Vermont, which was not a trifling request and has added great value to our respective work-life balances.
“I’m excited for the future of Boyds and am eager to be involved in shaping the continued growth in the US.”
Dr Katherine Bowen, Vice President, Regulatory Affairs adds: “This is a well-deserved promotion and recognizes the incredible value that Eric has brought not only through his regulatory expertise but his attitude and ability to connect with our clients and with the wider team at Boyds. Boyds is growing its reputation in the US, and well over half of our client projects now come from US businesses who are seeking our regulatory expertise as well as continuing to support global clients with their FDA strategy and interactions. As a valued member of the team, Eric is instrumental in supporting our exciting growth in the US.”
